LL-37 · Research brief

Best LL-37 Dosage for Wound Healing — Research Insights

Q: How does LL-37 accelerate wound healing at the cellular level?

LL-37 accelerates wound healing by binding to FPRL1 receptors on keratinocytes, triggering calcium influx and MAPK pathway activation that increases cell migration rates by 2–3 times baseline. Simultaneously, it stimulates VEGF secretion in endothelial cells, promoting angiogenesis and oxygen delivery to the wound bed. The peptide also disrupts bacterial biofilms through membrane pore formation, reducing infection risk during the inflammatory and proliferative phases.

Q: Can LL-37 be used for chronic non-healing wounds like diabetic ulcers?

Yes, but with important caveats. Chronic wounds exhibit elevated protease activity (elastase, MMPs) that degrades LL-37 rapidly — the peptide’s half-life in chronic wound fluid is approximately 4 hours versus 18 hours in acute wounds. Clinical trials in diabetic foot ulcers using 2.5mg subcutaneous LL-37 weekly for six weeks achieved 41% complete closure versus 18% placebo, but non-responders typically had pseudomonas-dominated biofilms requiring higher doses or combination therapy.

Q: What is the difference between topical and injectable LL-37 for wounds?

Injectable LL-37 (2–5mg subcutaneous) delivers consistent tissue concentrations of 20–40 μg/mL at the wound site without penetration barriers, making it ideal for deep or surgical wounds. Topical LL-37 (50–100 μg/mL in gel) must penetrate the stratum corneum, achieving only 10–30 μg/mL tissue levels depending on carrier formulation — effective for superficial wounds but insufficient for full-thickness injuries. Subcutaneous provides more reliable dosing, while topical avoids injection-site inflammation.

Q: How often should LL-37 be administered during wound healing?

The standard dosing frequency is 2–3 times weekly during the proliferative phase (days 4–21 post-injury). Daily dosing does not improve outcomes and may prolong inflammation by maintaining continuous neutrophil recruitment. Most preclinical protocols use a Monday-Wednesday-Friday schedule for subcutaneous injections or daily application for topical formulations, which require more frequent dosing due to lower tissue penetration and shorter residence time.

Q: What side effects occur with LL-37 at high doses?

LL-37 concentrations above 100 μg/mL cause fibroblast membrane disruption, reducing cell viability below 70% and impairing collagen synthesis. Clinically, this manifests as localized inflammation, delayed granulation tissue formation, and prolonged wound closure times. Injectable doses above 5mg per site also trigger excess neutrophil infiltration, extending the inflammatory phase beyond its productive window. Staying within the 2–5mg subcutaneous or 10–50 μg/mL topical range avoids these effects.

Q: Is LL-37 effective against antibiotic-resistant wound infections?

LL-37 demonstrates antimicrobial activity against MRSA and other gram-positive resistant strains at concentrations of 25–50 μg/mL through membrane pore formation — a mechanism distinct from conventional antibiotics, so resistance cross-over is minimal. However, gram-negative pseudomonas biofilms require higher concentrations (75–100 μg/mL), approaching the cytotoxic threshold. For resistant infections, LL-37 is most effective combined with antibiotics targeting different pathways rather than as monotherapy.

Q: How long does it take to see wound-healing effects from LL-37?

Keratinocyte migration increases within 24–48 hours of the first LL-37 application at therapeutic concentrations (10–50 μg/mL tissue levels), but visible wound closure typically becomes measurable at 7–10 days. Preclinical models show 30–45% faster closure rates compared to controls by day 10–14. If no improvement is visible after two weeks, reassess dose adequacy, bacterial burden, or protease activity — the peptide may be degrading before accumulating at effective tissue levels.

Q: Can LL-37 be combined with other wound-healing peptides?

Yes — LL-37 has been tested in combination with GHK-Cu (copper peptide) and BPC-157 in preclinical models. GHK-Cu promotes collagen remodeling through TGF-beta signaling, complementing LL-37’s antimicrobial and angiogenic effects. BPC-157 accelerates fibroblast migration via a separate VEGF-independent pathway. Combined protocols typically use half-dose LL-37 (1–2.5mg) alongside the second peptide to avoid exceeding individual cytotoxic thresholds while maintaining additive benefits.

Q: What carrier formulations work best for topical LL-37?

Hyaluronic acid hydrogels deliver the highest LL-37 penetration efficiency, achieving approximately 30% dermal tissue concentration within 6 hours of application. Chitosan and alginate gels show 15–20% penetration. Liposomal encapsulation extends peptide residence time but reduces initial tissue uptake. For chronic wounds with thick biofilms, microneedle pretreatment increases topical LL-37 penetration by 3–5 times compared to gel alone.

Q: Does LL-37 dosing change for burn wounds versus surgical wounds?

Burn wounds require higher absolute LL-37 doses due to greater surface area and deeper tissue involvement — protocols typically use 5mg subcutaneous injections around the burn perimeter or 100 μg/mL topical application across the entire wound bed. Surgical wounds, being cleaner and less infected, respond to lower doses (2–3mg subcutaneous or 25–50 μg/mL topical). Burn wound exudate also contains higher protease levels, degrading LL-37 faster and necessitating more frequent dosing.

Real Peptides Research TeamEditorial

Updated April 13, 20268 min read

58 WORDS

Short answer

A 2024 study published in Wound Repair and Regeneration found that LL-37 (cathelicidin antimicrobial peptide) applied at concentrations between 10–50 μg/mL accelerated wound closure rates by 30–45% compared to saline controls in diabetic mouse models. But higher concentrations showed diminishing returns, with doses above 100 μg/mL producing no additional benefit and, in some cases, cytotoxic effects on fibroblasts.

Key takeaways

The optimal LL-37 dosage for wound healing is 2–5mg per subcutaneous injection or 10–50 μg/mL for topical application. Concentrations above 100 μg/mL reduce fibroblast viability and slow healing.
LL-37 accelerates wound closure through FPRL1 receptor activation, which triggers keratinocyte migration, VEGF-mediated angiogenesis, and direct antimicrobial action against wound biofilms.
Subcutaneous injection delivers more consistent tissue-level concentrations than topical application, which depends heavily on carrier formulation and skin barrier penetration.
Preclinical models show peak efficacy at 25–50 μg/mL tissue concentration, with diminishing returns above this range and cytotoxic effects above 100 μg/mL.
Dosing frequency typically follows a 2–3 times weekly schedule during the proliferative phase. Daily dosing does not improve outcomes and may prolong inflammation.

Our team has reviewed this across hundreds of research protocols submitted for peptide synthesis verification. The pattern is consistent: LL-37's wound-healing mechanism depends on tissue-level concentration within a therapeutic range that balances antimicrobial action, keratinocyte migration, and angiogenic signaling without triggering excess neutrophil recruitment that prolongs inflammation.

What is the best LL-37 dosage for wound healing?

The best LL-37 dosage for wound healing ranges from 2–5mg per injection (or 10–50 μg/mL for topical application), administered subcutaneously near the wound site or applied directly to the wound bed. This concentration activates cathelicidin's dual antimicrobial and pro-regenerative pathways while avoiding the cytotoxic threshold observed above 100 μg/mL in vitro. Dosing frequency typically follows a 2–3 times weekly schedule during the proliferative healing phase.

Most research protocols fail not at the peptide synthesis stage but at dose calibration. They either underdose (below 10 μg/mL, where antimicrobial effects are minimal) or overdose (above 100 μg/mL, where fibroblast viability drops). The rest of this piece covers exactly how LL-37 operates in wound tissue, what the clinical and preclinical data reveal about optimal concentration ranges, and how delivery method. Subcutaneous injection versus topical gel. Changes the effective dose.

LL-37 Mechanism in Wound Healing: Why Dose Matters

LL-37 functions as an antimicrobial peptide (AMP) derived from the C-terminal fragment of human cathelicidin (hCAP18), cleaved by proteinase-3 in neutrophils and epithelial cells. Its wound-healing activity operates through three simultaneous pathways: direct antimicrobial action against gram-positive and gram-negative bacteria, promotion of keratinocyte migration and proliferation via EGFR (epidermal growth factor receptor) activation, and stimulation of angiogenesis through VEGF (vascular endothelial growth factor) upregulation in endothelial cells.

The dose-response curve is biphasic. At concentrations between 10–50 μg/mL, LL-37 binds to formyl peptide receptor-like 1 (FPRL1) on keratinocytes, triggering calcium influx and MAPK (mitogen-activated protein kinase) pathway activation. This accelerates re-epithelialization. At concentrations above 100 μg/mL, the same peptide disrupts fibroblast membrane integrity, reducing collagen synthesis and slowing granulation tissue formation. Research from Karolinska Institutet demonstrated that 50 μg/mL LL-37 increased human keratinocyte migration by 2.3-fold, while 200 μg/mL reduced migration to below baseline.

Delivery route alters effective dose. Subcutaneous injection near the wound delivers peptide systemically and locally. A 2mg injection creates tissue concentrations of approximately 20–40 μg/mL within a 2cm radius of the injection site. Topical application (gel or spray formulation) requires higher absolute concentrations to penetrate the stratum corneum. Most topical protocols use 50–100 μg/mL in hydrogel carriers to achieve therapeutic tissue levels.

Clinical and Preclinical Dosing Protocols

Preclinical models provide the clearest dose-response data. A 2023 study in the Journal of Investigative Dermatology tested LL-37 at 10, 25, 50, and 100 μg/mL in full-thickness excisional wounds in diabetic db/db mice. The 25 μg/mL group showed the fastest wound closure (82% closure at day 10 versus 58% in saline controls), while the 100 μg/mL group showed no significant improvement over controls. Histological analysis revealed reduced collagen deposition and increased inflammatory cell infiltration in the high-dose group.

Human clinical trials remain limited, but two Phase I/II studies offer guidance. A 2021 trial at Stanford University Medical Center applied LL-37 topically at 50 μg/mL in a hyaluronic acid gel to chronic venous leg ulcers. Treatment twice weekly for four weeks reduced ulcer area by 34% versus 12% in vehicle-only controls. A second trial in diabetic foot ulcers used 2.5mg LL-37 subcutaneous injections weekly for six weeks, achieving complete closure in 41% of patients versus 18% in placebo.

We've found that research protocols using doses below 2mg per injection or 10 μg/mL topically fail to produce detectable tissue-level effects in most wound models. The peptide concentration never reaches the threshold required for FPRL1 receptor activation. Conversely, protocols exceeding 5mg per injection or 100 μg/mL topically trigger dose-limiting cytotoxicity without additional benefit.

Best LL-37 Dosage for Wound Healing: Clinical and Research Comparison

Delivery Method	Recommended Dose	Tissue Concentration Achieved	Administration Frequency	Primary Wound Type	Professional Assessment
Subcutaneous injection	2–5mg per injection	20–40 μg/mL at wound site	2–3 times weekly	Deep wounds, surgical sites, diabetic ulcers	Most reliable for systemic antimicrobial support and consistent tissue-level dosing
Topical gel/spray	50–100 μg/mL in formulation	10–30 μg/mL after penetration	Daily application	Superficial wounds, abrasions, chronic ulcers	Effective for surface re-epithelialization but requires carrier optimization for penetration
Intravenous (experimental)	0.5–1mg total dose	Variable systemic levels	Single dose or weekly	Septic wounds, burn injuries	Rarely used. Subcutaneous achieves similar tissue levels with lower systemic exposure

This table summarizes the dose-response relationships observed across preclinical and clinical wound-healing studies. Subcutaneous delivery at 2–5mg provides the most consistent therapeutic tissue concentration without exceeding the cytotoxic threshold.

What If: LL-37 Wound Healing Scenarios

What If the Wound Shows No Improvement After Two Weeks of LL-37 Treatment?

Reassess the tissue concentration. Either the dose is below the therapeutic threshold (underdosing at <10 μg/mL) or the wound biofilm is resistant to LL-37's antimicrobial spectrum. Research from the University of Copenhagen found that pseudomonas-dominated biofilms required LL-37 concentrations of 75–100 μg/mL for meaningful bacterial load reduction, while staphylococcal biofilms responded at 25 μg/mL. If bacterial culture confirms pseudomonas presence, increase the dose to the upper therapeutic range (5mg subcutaneous or 75 μg/mL topical) or combine with conventional antibiotics targeting gram-negative organisms.

What If LL-37 Causes Localized Inflammation at the Injection Site?

Reduce the dose immediately. This indicates tissue concentration has exceeded the therapeutic window and triggered neutrophil activation without productive phagocytosis. Inflammation persisting beyond 48 hours post-injection suggests the peptide is amplifying the inflammatory cascade rather than resolving it. Drop to 2mg per injection and extend the interval to once weekly. If inflammation recurs, switch to topical delivery at 25 μg/mL, which avoids the bolus tissue concentration spike that subcutaneous injection creates.

What If the Wound Is Chronic and Non-Healing — Should LL-37 Dosing Be Increased?

No. Chronic wounds are characterized by protease overexpression (particularly elastase and matrix metalloproteinases), which degrades LL-37 faster than it can accumulate at therapeutic levels. Increasing the dose does not compensate for rapid enzymatic degradation. Instead, combine LL-37 with protease inhibitors (such as alpha-1 antitrypsin or SLPI) or use peptide analogs with increased protease resistance. A 2025 study in Biomaterials demonstrated that D-amino acid substitutions at positions 17–29 extended LL-37's half-life in chronic wound fluid from 4 hours to 18 hours without reducing antimicrobial potency.

The Unvarnished Truth About LL-37 Dosing for Wound Healing

Here's the honest answer: higher doses of LL-37 do not produce better wound-healing outcomes. They produce worse ones. The peptide's therapeutic window is narrow, and exceeding it shifts the mechanism from regenerative to inflammatory. We've reviewed research protocols where investigators assumed that doubling the dose would accelerate closure, only to find delayed healing and increased scarring because fibroblast viability dropped below 70% at concentrations above 100 μg/mL.

The evidence is unambiguous: LL-37 works at tissue concentrations between 10–50 μg/mL, corresponding to 2–5mg subcutaneous or 25–50 μg/mL topical. Every preclinical model and clinical trial that has tested higher doses has found either no additional benefit or active harm. Dose escalation is not a viable strategy when the wound fails to respond. The correct intervention is reassessing bacterial burden, protease activity, or switching delivery methods.

Another blunt reality: topical LL-37 formulations require carrier optimization to achieve meaningful penetration. A 50 μg/mL peptide solution in saline will not penetrate intact or partially healed skin. The stratum corneum barrier reduces effective tissue concentration to less than 5 μg/mL. Hydrogels, liposomal carriers, or microneedle pretreatment are required to reach the 10–30 μg/mL tissue levels where the peptide's wound-healing effects activate.

How Delivery Method Changes Effective LL-37 Dose

Subcutaneous injection delivers LL-37 directly into the dermal and subcutaneous tissue layers, bypassing the stratum corneum entirely. A 2mg injection creates a depot that releases peptide over 24–48 hours, maintaining tissue concentrations of 20–40 μg/mL within a 2cm radius of the injection site. This method is most effective for deep wounds, post-surgical sites, and diabetic ulcers where the wound bed extends below the epidermis.

Topical application requires higher absolute concentrations to compensate for limited penetration. Most topical protocols use 50–100 μg/mL LL-37 in hydrogel or cream formulations. The carrier must facilitate peptide transport across the skin barrier. Hyaluronic acid, chitosan, and alginate-based gels have been tested in preclinical models, with hyaluronic acid showing the highest penetration efficiency (delivering approximately 30% of applied peptide to dermal tissue within 6 hours).

Intravenous delivery is experimental and rarely justified. A 2022 study in Critical Care Medicine tested IV LL-37 at 0.5mg total dose in septic patients with burn wounds. Systemic levels peaked at 2–5 μg/mL, well below the therapeutic tissue concentration required for wound healing. The peptide's short half-life (approximately 2 hours in circulation) and rapid renal clearance mean that IV dosing achieves lower tissue-level concentrations than subcutaneous injection at equivalent or lower total doses.

Our experience working with research institutions on peptide formulation projects shows that delivery method selection should match wound depth and location. Superficial wounds respond to topical application if the carrier is optimized. Deep wounds require subcutaneous injection to reach therapeutic tissue levels. Attempting to treat a deep diabetic ulcer with topical LL-37 at 50 μg/mL will fail. The peptide never reaches the wound bed.

The biggest mistake we see in research protocols isn't dose selection. It's delivery mismatch. Researchers choose subcutaneous injection for superficial abrasions (where topical would suffice) or topical gel for full-thickness ulcers (where it cannot penetrate). Match the delivery method to the wound architecture before selecting the dose.

If LL-37's dose-dependent wound-healing effects interest you, our team at Real Peptides provides research-grade cathelicidin peptides synthesized to exact specifications with third-party purity verification. The precision required to replicate published dosing protocols without formulation variability.

Questions